Human Immunodeficiency Virus Infection Clinical Trial
Official title:
A Phase IIa, Randomized, Double-blind, Active-controlled, 12-week Study of Amdoxovir (Two Doses) Versus Tenofovir DF, in Combination With Zidovudine in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations.
This is a double-blind Phase 2a study to test the safety and efficacy of an investigational
HIV drug, amdoxovir (300 mg or 500 mg twice daily) compared with tenofovir DF 300 mg once
daily in HIV-1 infected antiretroviral therapy-experienced subjects who are currently
failing antiretroviral therapy. There are three treatment groups (N=45). Subjects will be
randomized to receive either amdoxovir 300 mg twice daily (n=15) or amdoxovir 500 mg twice
daily (n=15) or tenofovir DF 300 mg once daily (n=15); each in combination with zidovudine
300 mg twice daily.
The study will assess initially amdoxovir (300 mg or 500 mg twice daily) or tenofovir DF 300
mg once daily, both in combination zidovudine 300 mg twice daily plus failing third drug,
but then with lopinavir/ritonavir (400 mg/100 mg twice daily) after Week 2. Subjects who
received amdoxovir (300 mg or 500 mg twice daily) and benefited from the drug may choose to
enroll in the 36-week open-label study.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05981807 -
HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
|
||
| Completed |
NCT01490359 -
Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
|
N/A | |
| Completed |
NCT03143205 -
Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men
|
N/A | |
| Completed |
NCT02738138 -
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
|
Phase 3 | |
| Completed |
NCT01791465 -
Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults
|
Phase 4 | |
| Completed |
NCT01869634 -
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
|
Phase 4 | |
| Completed |
NCT01662336 -
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
|
N/A | |
| Completed |
NCT01328158 -
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
|
N/A | |
| Completed |
NCT01383005 -
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)
|
N/A | |
| Completed |
NCT00711009 -
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
|
Phase 3 | |
| Completed |
NCT02817451 -
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants
|
Phase 3 | |
| Completed |
NCT02214173 -
The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV
|
N/A | |
| Completed |
NCT03284645 -
Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids
|
||
| Active, not recruiting |
NCT05141422 -
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
|
Phase 1 | |
| Completed |
NCT01939197 -
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
|
Phase 2/Phase 3 | |
| Completed |
NCT01447680 -
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
|
N/A | |
| Not yet recruiting |
NCT05769413 -
Awareness of Osteoporosis in HIV Patients
|
||
| Withdrawn |
NCT01738555 -
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects
|
Phase 2 |